Review



microvue ch50 eq eia kit  (Quidel)


Bioz Verified Symbol Quidel is a verified supplier
Bioz Manufacturer Symbol Quidel manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Quidel microvue ch50 eq eia kit
    Paired PD complement biomarker changes during iptacopan treatment
    Microvue Ch50 Eq Eia Kit, supplied by Quidel, used in various techniques. Bioz Stars score: 96/100, based on 25 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+kit/CH50+Eq+ELISA/pmc13678011-114-2-1
    Average 96 stars, based on 25 article reviews
    microvue ch50 eq eia kit - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy"

    Article Title: Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy

    Journal: Kidney International Reports

    doi: 10.1016/j.ekir.2026.107087

    Paired PD complement biomarker changes during iptacopan treatment
    Figure Legend Snippet: Paired PD complement biomarker changes during iptacopan treatment

    Techniques Used: Biomarker Discovery

    Paired PD complement biomarker changes during pegcetacoplan treatment
    Figure Legend Snippet: Paired PD complement biomarker changes during pegcetacoplan treatment

    Techniques Used: Biomarker Discovery

    Pathway-based organization and patient-level interpretation of complement biomarkers during proximal complement inhibition. (a) Complement biomarkers are organized into 4 biologically related axes: C3 response, alternative pathway amplification and factor B turnover, terminal pathway control, and functional pathway activity. Pegcetacoplan inhibits C3/C3b, whereas iptacopan inhibits factor B. The curved arrow represents the alternative pathway amplification loop feeding back into C3 activation. (b) Patient-level classification of on-treatment pharmacodynamic biomarker profiles. LPDC, largely PD-concordant; PDC, PD-concordant; PDD, PD-discordant.
    Figure Legend Snippet: Pathway-based organization and patient-level interpretation of complement biomarkers during proximal complement inhibition. (a) Complement biomarkers are organized into 4 biologically related axes: C3 response, alternative pathway amplification and factor B turnover, terminal pathway control, and functional pathway activity. Pegcetacoplan inhibits C3/C3b, whereas iptacopan inhibits factor B. The curved arrow represents the alternative pathway amplification loop feeding back into C3 activation. (b) Patient-level classification of on-treatment pharmacodynamic biomarker profiles. LPDC, largely PD-concordant; PDC, PD-concordant; PDD, PD-discordant.

    Techniques Used: Inhibition, Amplification, Control, Functional Assay, Activity Assay, Activation Assay, Biomarker Discovery

    Expected on-treatment pharmacodynamic biomarker patterns during factor B and C3/C3b inhibition
    Figure Legend Snippet: Expected on-treatment pharmacodynamic biomarker patterns during factor B and C3/C3b inhibition

    Techniques Used: Biomarker Discovery, Inhibition

    Pathway activity before and after proximal complement inhibition with iptacopan or pegcetacoplan. (a) Alternative pathway activity (APFA) was suppressed after treatment in both cohorts. Several patients had absent or near-absent APFA at baseline, creating a floor effect. (b) Classical pathway activity (CH50) increased after iptacopan and was generally preserved or increased after pegcetacoplan. With iptacopan, CH50 recovery is consistent with AP blockade and recovery of circulating C3. With pegcetacoplan, preserved or increased CH50 should not be interpreted in isolation as absence of target engagement. (c) Immunofixation electrophoresis of patient serum mixed 1:1 with normal human serum under EDTA or EGTA/MgCl 2 conditions. EDTA suppresses complement activation, whereas EGTA/MgCl 2 permits AP activation. At baseline, C3 activation products (C3AP) were detectable under EGTA/MgCl 2 conditions. After treatment, these products disappeared in both treatment groups, consistent with suppression of fluid-phase AP activation. In pegcetacoplan-treated samples, a slower-migrating C3-reactive band was observed, compatible with pegcetacoplan-bound C3 (Peg-C3). Filled circles with solid lines = PDC; open circles with dashed lines = LPDC; triangles = PDD. EDTA, ethylenediaminetetraacetic acid; EGTA, ethylene glycol tetraacetic acid; LPDC, largely PD-concordant; PDC, PD-concordant; PDD, PD-discordant.
    Figure Legend Snippet: Pathway activity before and after proximal complement inhibition with iptacopan or pegcetacoplan. (a) Alternative pathway activity (APFA) was suppressed after treatment in both cohorts. Several patients had absent or near-absent APFA at baseline, creating a floor effect. (b) Classical pathway activity (CH50) increased after iptacopan and was generally preserved or increased after pegcetacoplan. With iptacopan, CH50 recovery is consistent with AP blockade and recovery of circulating C3. With pegcetacoplan, preserved or increased CH50 should not be interpreted in isolation as absence of target engagement. (c) Immunofixation electrophoresis of patient serum mixed 1:1 with normal human serum under EDTA or EGTA/MgCl 2 conditions. EDTA suppresses complement activation, whereas EGTA/MgCl 2 permits AP activation. At baseline, C3 activation products (C3AP) were detectable under EGTA/MgCl 2 conditions. After treatment, these products disappeared in both treatment groups, consistent with suppression of fluid-phase AP activation. In pegcetacoplan-treated samples, a slower-migrating C3-reactive band was observed, compatible with pegcetacoplan-bound C3 (Peg-C3). Filled circles with solid lines = PDC; open circles with dashed lines = LPDC; triangles = PDD. EDTA, ethylenediaminetetraacetic acid; EGTA, ethylene glycol tetraacetic acid; LPDC, largely PD-concordant; PDC, PD-concordant; PDD, PD-discordant.

    Techniques Used: Activity Assay, Inhibition, Isolation, Drug discovery, Electrophoresis, Activation Assay

    Pegcetacoplan fully suppresses AP activity but incompletely suppresses CH50 in vitro . (a) Pegcetacoplan was added to pooled normal human serum at increasing molar ratios relative to C3. AP functional activity (red line), measured with the Wieslab AP assay, was completely suppressed at approximately a 1:1 pegcetacoplan:C3 molar ratio. In contrast, CH50 (blue line) decreased but remained detectable even at a 4:1 ratio, indicating different sensitivities of the two functional assays to pegcetacoplan. (b) C3 immunofixation electrophoresis showed a concentration-dependent increase in a slower-migrating band consistent with pegcetacoplan-bound C3 (Peg-C3) and a corresponding reduction in free C3. Free C3 remained detectable even in the presence of excess pegcetacoplan. Purified C3, shown as the circled dot in the second lane, served as an antibody control. (c) Addition of increasing concentrations of CP40, a competing C3-binding peptide, reduced the pegcetacoplan-C3 band and increased the free-C3 band, supporting concentration-dependent and reversible binding of pegcetacoplan to C3.
    Figure Legend Snippet: Pegcetacoplan fully suppresses AP activity but incompletely suppresses CH50 in vitro . (a) Pegcetacoplan was added to pooled normal human serum at increasing molar ratios relative to C3. AP functional activity (red line), measured with the Wieslab AP assay, was completely suppressed at approximately a 1:1 pegcetacoplan:C3 molar ratio. In contrast, CH50 (blue line) decreased but remained detectable even at a 4:1 ratio, indicating different sensitivities of the two functional assays to pegcetacoplan. (b) C3 immunofixation electrophoresis showed a concentration-dependent increase in a slower-migrating band consistent with pegcetacoplan-bound C3 (Peg-C3) and a corresponding reduction in free C3. Free C3 remained detectable even in the presence of excess pegcetacoplan. Purified C3, shown as the circled dot in the second lane, served as an antibody control. (c) Addition of increasing concentrations of CP40, a competing C3-binding peptide, reduced the pegcetacoplan-C3 band and increased the free-C3 band, supporting concentration-dependent and reversible binding of pegcetacoplan to C3.

    Techniques Used: Activity Assay, In Vitro, Functional Assay, Electrophoresis, Concentration Assay, Purification, Control, Binding Assay

    Biomarker profile in Peg#6 during pegcetacoplan treatment and after post-transplant switch to iptacopan
    Figure Legend Snippet: Biomarker profile in Peg#6 during pegcetacoplan treatment and after post-transplant switch to iptacopan

    Techniques Used: Biomarker Discovery

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer.
    Article Snippet: .. YKL-40 levels were measured using an ELISA kit (Quidel Corporation, San Diego, CA, USA), following the manufacturer’s instructions. ..

    Article Title: Non-neuronal cholinergic stimulation favors bone mass accrual
    Article Snippet: Mechanical testing included the following machines: Instron 5569 (Instron Corp., Canton, MA, United States) and Vickers microhardness indenter machine (Clark CM100 AT, HT-CM-95605, Shawnee Mission, KS). .. Analyses of metabolic parameters included serum leptin (ELISA kit, Life Technologies, Gaithersburg, MD) and insulin (ELISA kit, B-Bridge International, BioCat, Cupertino, CA), C-terminal telopeptides of type I collagen (ELISA kit, RatLaps EIA (IDS)), IL-17, TNF-α, and IFN-γ (ELISA kits, eBioscience, San Diego, CA), urinary catecholamine (ELISA kit, BlueGene, Biotech, Shanghai, China), and creatinine (ELISA kit, Quidel Corporation, San Diego, CA). ..

    Article Title: Proof-of-principle for enhanced dentoalveolar mineralization using exogenous tissue-nonspecific alkaline phosphatase in the Hyp mouse model of X-linked hypophosphatemia
    Article Snippet: Serum samples were analyzed at the clinical pathology laboratory at the College of Veterinary Medicine, The Ohio State University, to measure levels of calcium (Ca 2+ ), phosphate (P i ), and circulating alkaline phosphatase (ALP) activity. .. ELISA was employed to measure levels of FGF23 using MicroVue mouse/rat FGF-23 (C-term) ELISA kit (QuidelOrtho) and to measure levels of PTH using MicroVue mouse/rat PTH 1-84 ELISA kit (QuidelOrtho). .. Following blood collection (described above), samples were transferred to BD microtainer tubes with lithium heparin/PST gel (Becton, Dickinson and Company).

    Article Title: Association of CRP and synovial fluid HMGB1 with Pain in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis: a cross-sectional study
    Article Snippet: Levels of IL-6 and IL-8 were determined using ELISA kits from R&D Systems (Minneapolis, MN, USA). .. The cartilage degradation marker C2C was measured using an ELISA kit from IBEX Pharmaceuticals Inc. (Montréal, Québec, Canada), and the bone resorption marker TRAP5b was quantified using an ELISA kit from Quidel Corporation, USA. ..

    Article Title: Genetic reduction or deletion of osteopontin in osteomalacic Hyp mice fails to ameliorate dentoalveolar defects
    Article Snippet: Serum from mice ( n = 5/genotype) was analyzed at the clinical pathology laboratory at the College of Veterinary Medicine (The Ohio State University) to analyze the levels of calcium, P i , and ALP in mouse serum. .. ELISA was performed to quantify levels of FGF23 using MicroVue mouse/rat FGF23 (C-term) ELISA kit (QuidelOrtho), and PTH levels were quantified by MicroVue mouse/Rat PTH 1-84 ELISA kit (QuidelOrtho). .. Following blood collection as previously outlined, blood samples were transferred into BD microtainer tubes containing lithium heparin/PST gel (Becton, Dickinson and Company) (50 μL).

    Article Title: Chronic Glomerular Thrombotic Microangiopathy in a 72-Year-Old Patient with B-Cell Chronic Lymphocytic Leukemia and IgG Lambda Paraprotein
    Article Snippet: .. The complement activation marker known as sC5b-9 was detected in EDTA plasma using a commercially available ELISA kit (MicroVue sC5b-9 Plus EIA, A029, QuidelOrtho, San Diego, CA, USA). ..

    Article Title: Constitutive activation of TGF-β receptor type I promotes cortical and cancellous bone formation in adult mice
    Article Snippet: Serum phosphorus and calcium levels were measured according to the manufacturer’s instructions (Stanbio Laboratory, Boerne, TX, USA; catalog numbers 0830−125 and 0155−225, respectively). .. Parathyroid hormone (PTH) levels were quantified using a commercially available ELISA kit (Quidel, San Diego, CA, USA; catalog number 60−2305), following the manufacturer’s protocol. .. The levels of cytokines IL-23, IL-1α, TNF-α, IFN-γ, MCP-1, IL-12p70, IL-1β, IL-10, IL-6, IL-27, IL-17A, IFN-β, and GM-CSF were measured by a multiplex bead-based assay (LEGENDplex TM ) following the manufacturer’s instructions (LEGENDplexTM; BioLegend, San Diego, CA, USA; catalog number 740446).

    Catecholamine ELISA:

    Article Title: Non-neuronal cholinergic stimulation favors bone mass accrual
    Article Snippet: Mechanical testing included the following machines: Instron 5569 (Instron Corp., Canton, MA, United States) and Vickers microhardness indenter machine (Clark CM100 AT, HT-CM-95605, Shawnee Mission, KS). .. Analyses of metabolic parameters included serum leptin (ELISA kit, Life Technologies, Gaithersburg, MD) and insulin (ELISA kit, B-Bridge International, BioCat, Cupertino, CA), C-terminal telopeptides of type I collagen (ELISA kit, RatLaps EIA (IDS)), IL-17, TNF-α, and IFN-γ (ELISA kits, eBioscience, San Diego, CA), urinary catecholamine (ELISA kit, BlueGene, Biotech, Shanghai, China), and creatinine (ELISA kit, Quidel Corporation, San Diego, CA). ..

    other:

    Article Title: Disruption of the FGFR1-FGF23-Phosphate Axis and Targeted Therapy in a Murine Model of Osteoglophonic Dysplasia
    Article Snippet: The inorganic phosphate concentrations for 18 WT and 6 Fgfr1 +/N330I mice were measured either by IDEXX BioAnalytics or by the Division of Veterinary Resources at the NIH.

    Marker:

    Article Title: Association of CRP and synovial fluid HMGB1 with Pain in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis: a cross-sectional study
    Article Snippet: Levels of IL-6 and IL-8 were determined using ELISA kits from R&D Systems (Minneapolis, MN, USA). .. The cartilage degradation marker C2C was measured using an ELISA kit from IBEX Pharmaceuticals Inc. (Montréal, Québec, Canada), and the bone resorption marker TRAP5b was quantified using an ELISA kit from Quidel Corporation, USA. ..

    Article Title: Chronic Glomerular Thrombotic Microangiopathy in a 72-Year-Old Patient with B-Cell Chronic Lymphocytic Leukemia and IgG Lambda Paraprotein
    Article Snippet: .. The complement activation marker known as sC5b-9 was detected in EDTA plasma using a commercially available ELISA kit (MicroVue sC5b-9 Plus EIA, A029, QuidelOrtho, San Diego, CA, USA). ..

    Activation Assay:

    Article Title: Chronic Glomerular Thrombotic Microangiopathy in a 72-Year-Old Patient with B-Cell Chronic Lymphocytic Leukemia and IgG Lambda Paraprotein
    Article Snippet: .. The complement activation marker known as sC5b-9 was detected in EDTA plasma using a commercially available ELISA kit (MicroVue sC5b-9 Plus EIA, A029, QuidelOrtho, San Diego, CA, USA). ..

    Clinical Proteomics:

    Article Title: Chronic Glomerular Thrombotic Microangiopathy in a 72-Year-Old Patient with B-Cell Chronic Lymphocytic Leukemia and IgG Lambda Paraprotein
    Article Snippet: .. The complement activation marker known as sC5b-9 was detected in EDTA plasma using a commercially available ELISA kit (MicroVue sC5b-9 Plus EIA, A029, QuidelOrtho, San Diego, CA, USA). ..



    Similar Products

    94
    Guangzhou JET Bio-Filtration mouse ang1-7 (angiotensin?1-7) elisa?kit
    Mouse Ang1 7 (Angiotensin?1 7) Elisa?Kit, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+kit/Mouse+Ang1-7+(Angiotensin%3F1-7)+ELISA%3FKit/custom%40e-el-m2681%4042892631
    Average 94 stars, based on 1 article reviews
    mouse ang1-7 (angiotensin?1-7) elisa?kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    96
    Quidel microvue ch50 eq eia kit
    Paired PD complement biomarker changes during iptacopan treatment
    Microvue Ch50 Eq Eia Kit, supplied by Quidel, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+kit/CH50+Eq+ELISA/pmc13678011-114-2-1
    Average 96 stars, based on 1 article reviews
    microvue ch50 eq eia kit - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    86
    Jingmei Biotech Co Ltd elisa kits
    Paired PD complement biomarker changes during iptacopan treatment
    Elisa Kits, supplied by Jingmei Biotech Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+kit/elisa+kits/pmc13264186-370-15-17
    Average 86 stars, based on 1 article reviews
    elisa kits - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Dakewe Biotech Co mouse il 22 precoated elisa kit
    BacGuard promotes colon tissue repairment. a) Scheme of microbiota-dependent epithelial repair mechanism orchestrated by BacGuard. b) Short-chain fatty acid (SCFA) profile alterations. n = 6. c) BacGuard-induced probiotic proliferation and d) quantitative results. n = 3. e) Immunofluorescence analysis of ILC3 (ROR γt + CD3 − cells) in colon tissue. f) Flow cytometric analysis of lamina propria lymphocytes (ROR γt + ). n = 3. g) Concentration <t>of</t> <t>IL-22</t> in MNK-3 cells. n = 3. h) Representative PAS-staining (upper panel) and MUC-2 immunohistochemistry (lower panel) images of colon tissues. n = 5. ns, not significant; ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.
    Mouse Il 22 Precoated Elisa Kit, supplied by Dakewe Biotech Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+kit/1+elisa+il+kit+mouse+precoated+%CE%B2/pmc13264189-152-9-14
    Average 86 stars, based on 1 article reviews
    mouse il 22 precoated elisa kit - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    93
    Cusabio enzyme linked immunosorbent assay elisa kits
    BacGuard promotes colon tissue repairment. a) Scheme of microbiota-dependent epithelial repair mechanism orchestrated by BacGuard. b) Short-chain fatty acid (SCFA) profile alterations. n = 6. c) BacGuard-induced probiotic proliferation and d) quantitative results. n = 3. e) Immunofluorescence analysis of ILC3 (ROR γt + CD3 − cells) in colon tissue. f) Flow cytometric analysis of lamina propria lymphocytes (ROR γt + ). n = 3. g) Concentration <t>of</t> <t>IL-22</t> in MNK-3 cells. n = 3. h) Representative PAS-staining (upper panel) and MUC-2 immunohistochemistry (lower panel) images of colon tissues. n = 5. ns, not significant; ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.
    Enzyme Linked Immunosorbent Assay Elisa Kits, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+kit/Fish+Thyroxine%2CT4+ELISA+Kit/pm42894109-97-13-18
    Average 93 stars, based on 1 article reviews
    enzyme linked immunosorbent assay elisa kits - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    Cusabio human serum irisin concentrations
    BacGuard promotes colon tissue repairment. a) Scheme of microbiota-dependent epithelial repair mechanism orchestrated by BacGuard. b) Short-chain fatty acid (SCFA) profile alterations. n = 6. c) BacGuard-induced probiotic proliferation and d) quantitative results. n = 3. e) Immunofluorescence analysis of ILC3 (ROR γt + CD3 − cells) in colon tissue. f) Flow cytometric analysis of lamina propria lymphocytes (ROR γt + ). n = 3. g) Concentration <t>of</t> <t>IL-22</t> in MNK-3 cells. n = 3. h) Representative PAS-staining (upper panel) and MUC-2 immunohistochemistry (lower panel) images of colon tissues. n = 5. ns, not significant; ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.
    Human Serum Irisin Concentrations, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+kit/Human+irisin+ELISA+kit/pm42891762-100-1-15
    Average 93 stars, based on 1 article reviews
    human serum irisin concentrations - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    RayBiotech inc human troponin t elisa kit
    BacGuard promotes colon tissue repairment. a) Scheme of microbiota-dependent epithelial repair mechanism orchestrated by BacGuard. b) Short-chain fatty acid (SCFA) profile alterations. n = 6. c) BacGuard-induced probiotic proliferation and d) quantitative results. n = 3. e) Immunofluorescence analysis of ILC3 (ROR γt + CD3 − cells) in colon tissue. f) Flow cytometric analysis of lamina propria lymphocytes (ROR γt + ). n = 3. g) Concentration <t>of</t> <t>IL-22</t> in MNK-3 cells. n = 3. h) Representative PAS-staining (upper panel) and MUC-2 immunohistochemistry (lower panel) images of colon tissues. n = 5. ns, not significant; ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.
    Human Troponin T Elisa Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+kit/Human+Troponin+T+ELISA/pm42894062-80-7-6
    Average 94 stars, based on 1 article reviews
    human troponin t elisa kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    Elabscience Biotechnology 200 oxidative stress kits measurement 201
    BacGuard promotes colon tissue repairment. a) Scheme of microbiota-dependent epithelial repair mechanism orchestrated by BacGuard. b) Short-chain fatty acid (SCFA) profile alterations. n = 6. c) BacGuard-induced probiotic proliferation and d) quantitative results. n = 3. e) Immunofluorescence analysis of ILC3 (ROR γt + CD3 − cells) in colon tissue. f) Flow cytometric analysis of lamina propria lymphocytes (ROR γt + ). n = 3. g) Concentration <t>of</t> <t>IL-22</t> in MNK-3 cells. n = 3. h) Representative PAS-staining (upper panel) and MUC-2 immunohistochemistry (lower panel) images of colon tissues. n = 5. ns, not significant; ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.
    200 Oxidative Stress Kits Measurement 201, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+kit/NA%2FNE+(Noradrenaline%2FNorepinephrine)+ELISA+Kit/pm42893735-120-10-28
    Average 95 stars, based on 1 article reviews
    200 oxidative stress kits measurement 201 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    94
    Elabscience Biotechnology human elisa kits
    BacGuard promotes colon tissue repairment. a) Scheme of microbiota-dependent epithelial repair mechanism orchestrated by BacGuard. b) Short-chain fatty acid (SCFA) profile alterations. n = 6. c) BacGuard-induced probiotic proliferation and d) quantitative results. n = 3. e) Immunofluorescence analysis of ILC3 (ROR γt + CD3 − cells) in colon tissue. f) Flow cytometric analysis of lamina propria lymphocytes (ROR γt + ). n = 3. g) Concentration <t>of</t> <t>IL-22</t> in MNK-3 cells. n = 3. h) Representative PAS-staining (upper panel) and MUC-2 immunohistochemistry (lower panel) images of colon tissues. n = 5. ns, not significant; ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.
    Human Elisa Kits, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+kit/Human+Ang-%E2%85%A1+(Angiotensin+%E2%85%A1)+ELISA+Kit/pm42892631-72-18-21
    Average 94 stars, based on 1 article reviews
    human elisa kits - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    Elabscience Biotechnology nt probnp
    BacGuard promotes colon tissue repairment. a) Scheme of microbiota-dependent epithelial repair mechanism orchestrated by BacGuard. b) Short-chain fatty acid (SCFA) profile alterations. n = 6. c) BacGuard-induced probiotic proliferation and d) quantitative results. n = 3. e) Immunofluorescence analysis of ILC3 (ROR γt + CD3 − cells) in colon tissue. f) Flow cytometric analysis of lamina propria lymphocytes (ROR γt + ). n = 3. g) Concentration <t>of</t> <t>IL-22</t> in MNK-3 cells. n = 3. h) Representative PAS-staining (upper panel) and MUC-2 immunohistochemistry (lower panel) images of colon tissues. n = 5. ns, not significant; ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.
    Nt Probnp, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/elisa+kit/Mouse+NT-proBNP+(N-terminal+pro-Brain+Natriuretic+Peptide)+ELISA+Kit/pm42893735-120-32-34
    Average 95 stars, based on 1 article reviews
    nt probnp - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    Paired PD complement biomarker changes during iptacopan treatment

    Journal: Kidney International Reports

    Article Title: Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy

    doi: 10.1016/j.ekir.2026.107087

    Figure Lengend Snippet: Paired PD complement biomarker changes during iptacopan treatment

    Article Snippet: The Quidel MicroVue CH50 Eq EIA kit was used only for the pegcetacoplan spiking experiments.

    Techniques: Biomarker Discovery

    Paired PD complement biomarker changes during pegcetacoplan treatment

    Journal: Kidney International Reports

    Article Title: Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy

    doi: 10.1016/j.ekir.2026.107087

    Figure Lengend Snippet: Paired PD complement biomarker changes during pegcetacoplan treatment

    Article Snippet: The Quidel MicroVue CH50 Eq EIA kit was used only for the pegcetacoplan spiking experiments.

    Techniques: Biomarker Discovery

    Pathway-based organization and patient-level interpretation of complement biomarkers during proximal complement inhibition. (a) Complement biomarkers are organized into 4 biologically related axes: C3 response, alternative pathway amplification and factor B turnover, terminal pathway control, and functional pathway activity. Pegcetacoplan inhibits C3/C3b, whereas iptacopan inhibits factor B. The curved arrow represents the alternative pathway amplification loop feeding back into C3 activation. (b) Patient-level classification of on-treatment pharmacodynamic biomarker profiles. LPDC, largely PD-concordant; PDC, PD-concordant; PDD, PD-discordant.

    Journal: Kidney International Reports

    Article Title: Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy

    doi: 10.1016/j.ekir.2026.107087

    Figure Lengend Snippet: Pathway-based organization and patient-level interpretation of complement biomarkers during proximal complement inhibition. (a) Complement biomarkers are organized into 4 biologically related axes: C3 response, alternative pathway amplification and factor B turnover, terminal pathway control, and functional pathway activity. Pegcetacoplan inhibits C3/C3b, whereas iptacopan inhibits factor B. The curved arrow represents the alternative pathway amplification loop feeding back into C3 activation. (b) Patient-level classification of on-treatment pharmacodynamic biomarker profiles. LPDC, largely PD-concordant; PDC, PD-concordant; PDD, PD-discordant.

    Article Snippet: The Quidel MicroVue CH50 Eq EIA kit was used only for the pegcetacoplan spiking experiments.

    Techniques: Inhibition, Amplification, Control, Functional Assay, Activity Assay, Activation Assay, Biomarker Discovery

    Expected on-treatment pharmacodynamic biomarker patterns during factor B and C3/C3b inhibition

    Journal: Kidney International Reports

    Article Title: Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy

    doi: 10.1016/j.ekir.2026.107087

    Figure Lengend Snippet: Expected on-treatment pharmacodynamic biomarker patterns during factor B and C3/C3b inhibition

    Article Snippet: The Quidel MicroVue CH50 Eq EIA kit was used only for the pegcetacoplan spiking experiments.

    Techniques: Biomarker Discovery, Inhibition

    Pathway activity before and after proximal complement inhibition with iptacopan or pegcetacoplan. (a) Alternative pathway activity (APFA) was suppressed after treatment in both cohorts. Several patients had absent or near-absent APFA at baseline, creating a floor effect. (b) Classical pathway activity (CH50) increased after iptacopan and was generally preserved or increased after pegcetacoplan. With iptacopan, CH50 recovery is consistent with AP blockade and recovery of circulating C3. With pegcetacoplan, preserved or increased CH50 should not be interpreted in isolation as absence of target engagement. (c) Immunofixation electrophoresis of patient serum mixed 1:1 with normal human serum under EDTA or EGTA/MgCl 2 conditions. EDTA suppresses complement activation, whereas EGTA/MgCl 2 permits AP activation. At baseline, C3 activation products (C3AP) were detectable under EGTA/MgCl 2 conditions. After treatment, these products disappeared in both treatment groups, consistent with suppression of fluid-phase AP activation. In pegcetacoplan-treated samples, a slower-migrating C3-reactive band was observed, compatible with pegcetacoplan-bound C3 (Peg-C3). Filled circles with solid lines = PDC; open circles with dashed lines = LPDC; triangles = PDD. EDTA, ethylenediaminetetraacetic acid; EGTA, ethylene glycol tetraacetic acid; LPDC, largely PD-concordant; PDC, PD-concordant; PDD, PD-discordant.

    Journal: Kidney International Reports

    Article Title: Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy

    doi: 10.1016/j.ekir.2026.107087

    Figure Lengend Snippet: Pathway activity before and after proximal complement inhibition with iptacopan or pegcetacoplan. (a) Alternative pathway activity (APFA) was suppressed after treatment in both cohorts. Several patients had absent or near-absent APFA at baseline, creating a floor effect. (b) Classical pathway activity (CH50) increased after iptacopan and was generally preserved or increased after pegcetacoplan. With iptacopan, CH50 recovery is consistent with AP blockade and recovery of circulating C3. With pegcetacoplan, preserved or increased CH50 should not be interpreted in isolation as absence of target engagement. (c) Immunofixation electrophoresis of patient serum mixed 1:1 with normal human serum under EDTA or EGTA/MgCl 2 conditions. EDTA suppresses complement activation, whereas EGTA/MgCl 2 permits AP activation. At baseline, C3 activation products (C3AP) were detectable under EGTA/MgCl 2 conditions. After treatment, these products disappeared in both treatment groups, consistent with suppression of fluid-phase AP activation. In pegcetacoplan-treated samples, a slower-migrating C3-reactive band was observed, compatible with pegcetacoplan-bound C3 (Peg-C3). Filled circles with solid lines = PDC; open circles with dashed lines = LPDC; triangles = PDD. EDTA, ethylenediaminetetraacetic acid; EGTA, ethylene glycol tetraacetic acid; LPDC, largely PD-concordant; PDC, PD-concordant; PDD, PD-discordant.

    Article Snippet: The Quidel MicroVue CH50 Eq EIA kit was used only for the pegcetacoplan spiking experiments.

    Techniques: Activity Assay, Inhibition, Isolation, Drug discovery, Electrophoresis, Activation Assay

    Pegcetacoplan fully suppresses AP activity but incompletely suppresses CH50 in vitro . (a) Pegcetacoplan was added to pooled normal human serum at increasing molar ratios relative to C3. AP functional activity (red line), measured with the Wieslab AP assay, was completely suppressed at approximately a 1:1 pegcetacoplan:C3 molar ratio. In contrast, CH50 (blue line) decreased but remained detectable even at a 4:1 ratio, indicating different sensitivities of the two functional assays to pegcetacoplan. (b) C3 immunofixation electrophoresis showed a concentration-dependent increase in a slower-migrating band consistent with pegcetacoplan-bound C3 (Peg-C3) and a corresponding reduction in free C3. Free C3 remained detectable even in the presence of excess pegcetacoplan. Purified C3, shown as the circled dot in the second lane, served as an antibody control. (c) Addition of increasing concentrations of CP40, a competing C3-binding peptide, reduced the pegcetacoplan-C3 band and increased the free-C3 band, supporting concentration-dependent and reversible binding of pegcetacoplan to C3.

    Journal: Kidney International Reports

    Article Title: Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy

    doi: 10.1016/j.ekir.2026.107087

    Figure Lengend Snippet: Pegcetacoplan fully suppresses AP activity but incompletely suppresses CH50 in vitro . (a) Pegcetacoplan was added to pooled normal human serum at increasing molar ratios relative to C3. AP functional activity (red line), measured with the Wieslab AP assay, was completely suppressed at approximately a 1:1 pegcetacoplan:C3 molar ratio. In contrast, CH50 (blue line) decreased but remained detectable even at a 4:1 ratio, indicating different sensitivities of the two functional assays to pegcetacoplan. (b) C3 immunofixation electrophoresis showed a concentration-dependent increase in a slower-migrating band consistent with pegcetacoplan-bound C3 (Peg-C3) and a corresponding reduction in free C3. Free C3 remained detectable even in the presence of excess pegcetacoplan. Purified C3, shown as the circled dot in the second lane, served as an antibody control. (c) Addition of increasing concentrations of CP40, a competing C3-binding peptide, reduced the pegcetacoplan-C3 band and increased the free-C3 band, supporting concentration-dependent and reversible binding of pegcetacoplan to C3.

    Article Snippet: The Quidel MicroVue CH50 Eq EIA kit was used only for the pegcetacoplan spiking experiments.

    Techniques: Activity Assay, In Vitro, Functional Assay, Electrophoresis, Concentration Assay, Purification, Control, Binding Assay

    Biomarker profile in Peg#6 during pegcetacoplan treatment and after post-transplant switch to iptacopan

    Journal: Kidney International Reports

    Article Title: Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy

    doi: 10.1016/j.ekir.2026.107087

    Figure Lengend Snippet: Biomarker profile in Peg#6 during pegcetacoplan treatment and after post-transplant switch to iptacopan

    Article Snippet: The Quidel MicroVue CH50 Eq EIA kit was used only for the pegcetacoplan spiking experiments.

    Techniques: Biomarker Discovery

    BacGuard promotes colon tissue repairment. a) Scheme of microbiota-dependent epithelial repair mechanism orchestrated by BacGuard. b) Short-chain fatty acid (SCFA) profile alterations. n = 6. c) BacGuard-induced probiotic proliferation and d) quantitative results. n = 3. e) Immunofluorescence analysis of ILC3 (ROR γt + CD3 − cells) in colon tissue. f) Flow cytometric analysis of lamina propria lymphocytes (ROR γt + ). n = 3. g) Concentration of IL-22 in MNK-3 cells. n = 3. h) Representative PAS-staining (upper panel) and MUC-2 immunohistochemistry (lower panel) images of colon tissues. n = 5. ns, not significant; ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.

    Journal: Bioactive Materials

    Article Title: Dynamic feedback BacGuard anchors microbial metabolism to host symbiosis in real-time ulcerative colitis therapy

    doi: 10.1016/j.bioactmat.2026.05.060

    Figure Lengend Snippet: BacGuard promotes colon tissue repairment. a) Scheme of microbiota-dependent epithelial repair mechanism orchestrated by BacGuard. b) Short-chain fatty acid (SCFA) profile alterations. n = 6. c) BacGuard-induced probiotic proliferation and d) quantitative results. n = 3. e) Immunofluorescence analysis of ILC3 (ROR γt + CD3 − cells) in colon tissue. f) Flow cytometric analysis of lamina propria lymphocytes (ROR γt + ). n = 3. g) Concentration of IL-22 in MNK-3 cells. n = 3. h) Representative PAS-staining (upper panel) and MUC-2 immunohistochemistry (lower panel) images of colon tissues. n = 5. ns, not significant; ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001.

    Article Snippet: For the detection of IL-22 and LPS concentrations, the Mouse IL-22 Precoated ELISA Kit (DAKEWE, China) and Mouse LPS ELISA Kit (JONLNBIO, China) were employed correspondingly.

    Techniques: Immunofluorescence, Concentration Assay, Staining, Immunohistochemistry